No abstract

The impact of continuous arteriovenous haemodiafiltration (CAVHD) on nitrogen, lipid and carbohydrate balance was studied in 9 parenterally fed critically ill patients with acute renal failure. The effects on carbohydrate delivery of varying dialysate glucose concentrations or flow rates were also investigated. The total daily nitrogen loss was a mean of 24.1 g (95% CI 20.9-27.3 g/24 h) with non-urea nitrogen losses of 7.6 g (95% CI 5.6-9.6 g/24 h). Glucose delivery was a mean 5.8 g/h with a dialysate glucose concentration of 1.5% and a flow rate of 1 l/h (95% CI 4.5-7.0 g/h). Carbohydrate delivery increased with increased dialysate glucose concentration (mean 11.4 g/h with 2.5% glucose: 95% CI 9.6-13.1 g/h; mean 14.9 g/h with a 4.25% concentration: 95% CI 10.9-19; and with increased dialysate flow rates (mean 9.6 g/h, 95% CI 6.8-12.4 g/h, using 2 l/h of 1.5% glucose). Only trace amounts of cholesterol and/or triglycerides were detected in occasional ultradiafiltrate samples. CAVHD has an important impact on nitrogen and carbohydrate balance, but not on lipid status. Knowledge of these interactions is crucial for the rational planning of nutritional strategies in the critically ill.

We have prospectivly investigated the effect of a flexible approach to the management of acute renal failure in critically ill patients based on continuous haemodiafiltration (CHD). Fifty critically ill patients (mean APACHE II score 28.1, range 18-37), with a mean age of 59.5 years, were treated with continuous arteriovenous haemodiafiltration (CAVHD) and/or continuous venovenous haemodiafiltration (CWHD). CHD achieved excellent haemodynamic stability and control of azotaemia in all patients and permitted aggressive parenteral nutrition. The mean blood urea concentration fell from 33.9 mmol/l (95% confidence interval, CI, 29.1-38.7) to a plateau of 17 mmol/l (95% CI 14.3-19.7) after 72 h of therapy despite persistent anuria and the parenteral administration of 0.3g/kday of protein nitrogen (mean urea clearance: 24.2ml/min; 95% CI 22.9-25.5). No supplemental dialytic therapy was required during the 9,485 h of treatment. All clinically significant complications related to vascular access (14%). Twenty-two patients (44%) survived to be discharged from the ICU. CHD is relatively safe and effective in the management of acute renal failure in the critically ill.

We report the results of continuous arteriovenous haemodiafiltration (CAVHD) treatment in 12 critically ill intensive care patients with acute renal failure (eight males, four females - mean age 60.9 years - range 47 to 76) (APACHE II score 28.8, range 18-37). All patients were oligoanuric or had a rising creatinine (greater than or equal to 100 microM/L per day). Vascular access was obtained by Scribner shunt or wide-bore femoral arterial and venous cannulae. At the beginning of CAVHD therapy the mean plasma urea was 38 mM/L (SE 4.5, 95% confidence interval (CI) 25.1 to 75.6 mM/L) and the mean creatinine was 604 microM/L (SE 70, 95% CI 450-756 microM/L). After 72 hours of therapy, despite oligoanuria, urea concentration had fallen to a mean of 15.7 mM/L (SE 2.4, 95% CI 12.5-22.9 mM/L) and the creatinine concentration to 297 microM/L (SE 25, 95% CI 243-351 microM/L), respectively. The mean ultrafiltrate volume was 441 mL/hr (SE 33, 95%, range 50-1050 mL/hr). There were no complications related to the extracorporeal circuit, the filter, anticoagulant therapy, electrolyte status or changes in patients' haemodynamic state. Excellent biochemical control of azotaemia was uniformly achieved during CAVHD therapy. Five patients (41.6%) survived to be discharged from the Intensive Care Unit. CAVHD is a simple, safe and effective continuous renal replacement therapy. CAVHD offers technical advantages over alternative therapy while providing equivalent or better biochemical control of azotaemia and volume status in critically ill patients with acute renal failure.

IN December 1976 a 3-cm acoustic neuroma was removed from a 37-year-old Woman. A combined suboccipital and retrolabyrinthine approach was used, anatomically sparing the facial nerve. During the last stages of tumor removal from the Internal auditory canal, the facial nerve was stimulated using a Week disposable stimulator. The face was observed to move well with stimulation, although the 2-mamp setting was required. Observation through the operating microscope at 16 power magnification showed that the stimulator actually blanched the neural sheath and bubbled the surface fluids. The stimulator was then applied to the dura, the edge of which curled as if cauterized. Six months postoperatively the patient has yet to regain facial function.Subsequent clinical applications were observed when the marginal mandibularis branch of the facial nerve was stimulated during a submaxillary gland removal. A paresis of this branch resulted, TX 77550 (Mrs Suzanne Crow). lasting four months with eventual full recovery. Another case prompted more study when, during a parotidectomy, the stimulator tip visualized through the operating microscope appeared to cauterize a small vessel.Although absolute conclusions from such observations cannot be made, several points were obvious: (1) Few observations of the tissues stimulated are made due to the usual short length of stimulation and the failure to visualize the field through the operating microscope. (2) Some careful studies should be instigated to determine any deleterious effect, if any, upon normal nerve tissue.Immediate steps were taken to employ careful use of the stimulator and to use the operating microscope whenever possible. Studies were then begun to evaluate the stimulator and its effect upon tissues.